Back to search results

Green Light Therapy for Fibromyalgia Pain

This study is looking into how green light therapy (Green Light) helps people with fibromyalgia. Researchers have seen that green light can reduce pain in previous studies, but they want to understand exactly how it works in the body. You might be able to join if you are 18 or older, speak English, have been diagnosed with fibromyalgia using specific criteria, and have an average pain score of 5 out of 10 or higher that hasn't been controlled by other treatments. The main goal is to see if Green Light decreases the activity of certain brain cells called glial cells. The study is currently recruiting 70 participants, but its overall status is unclear.

Study design
This is an interventional study planning to enroll 70 participants. It is not specified if it is randomized or blinded.
What's involved
You would have initial tests over 1-2 days, including surveys, pain threshold measurements, a spinal fluid collection (CSF), and a brain scan (PET scan). Then you would start 10 weeks of light therapy, with phone check-ins every two weeks. At the end of 10 weeks, you would repeat the initial tests.
Compensation
Not stated in the trial record.
Follow-up
You will be followed for 10 to 22 weeks, depending on which study group you are in.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05569486

Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain

Not Yet Recruiting
NAAges 18+InterventionalTreatment
University of Arizona
~70 participants
Updated 2026-04-03 on ClinicalTrials.gov
What's tested:Green Light

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Decreased activation of glial cells.
Measured over [Time Frame: 10 - 22 weeks, depending on study arm]

Conditions

Fibromyalgia

Explore related trials

Fibromyalgia

Where it's being run

1 sites across 1 states
Arizona1

Study leadership

  • Mohab M Ibrahim, PhD., MD · PRINCIPAL_INVESTIGATOR · University of Arizona

Who to contact

Mohab M Ibrahim, PhD., MD
[email protected]
520-871-7246
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

18 years or older who can speak and understand English
Meets the diagnostic criteria for fibromyalgia accroding to the 2016 revisions to the 2010/2011 fibromyalgia diagnostic criteria.
Average numeric pain score of 5 out of 10 or greater over the 10 weeks prior to enrolling in the study, and failure of medical therapy to control their pain.

Exclusion

Serious mental illness defined as distortions of perception, delusions, hallucinations, and unusual behaviors resulting in loss of contact with reality. This will be assessed during the screening interview. Patients with psychiatric disorders will have their medical record reviewed prior to enrollment
History of color blindness or uncorrected cataracts
Subjects receiving remuneration for their medical condition.
Genotype of low affinity binders for translocator protein, (TSPO), as patients with low affinity binding TSPO may not have adequate uptake for the radioactive tracer used for the PET scan.

What this trial measures

  • Decreased activation of glial cells.[Time Frame: 10 - 22 weeks, depending on study arm]

    By exposure to GLED investigators hypothesize that glial cells will be decreased, investigators will measure this by using positron emission tomography (PET) scan, scans will be conducted at baseline and the end of study